Summary
Bromocriptine and the two ergoline derivatives, CQ 32-084 and CM 29-712, excert dopamine-like effects in experimental models and have been shown to possess antiparkinsonian activity. Biochemical investigations indicate that they differ in their specificity towards the different dopamine receptor types and, in addition, interact with other neurotransmitter receptors. Bromocriptine appears to be a potent agonist at D2-receptors. Furthermore, it blocks adenylate cyclase coupled serotonin receptors and antagonizes centralα-adrenergic receptors. The two ergoline derivatives are multiple agonists. CQ 32-084 stimulates both D1- and D2-, and CM 29-712 only D2-receptors. In addition, both compounds stimulate adenylate cyclase coupled serotonin receptors and antagonize centralα-adrenergic receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agnati, L. F., Fuxe, K.: On the mechanism of antiparkinsonian action of L-DOPA and bromocriptine: A theoretical and experimental analysis of dopamine receptor sub- and supersensitivity. J. Neural Transm., Suppl. 16, pp. 69–81. Wien-New York: Springer. 1980.
Bürki, H. R., Asper, H., Ruch, W., Züger, P. E.: Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF 25-397 and 29-712. Effects on the metabolism of the biogenic amines in the brain of the rat. Psychopharmac.57, 227–237 (1978).
Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., Petrie, A.: Bromocriptine in parkinsonism. Brit. med. J.4, 442 to 444 (1974).
Closse, A., Frick, W., Hauser, D., Sauter, A.: Characterization of3H-bromocriptine binding to calf caudate membranes. In: Psychopharmacology and Biochemistry of Neurotransmitter Receptors (Olsen, R. W., Yamamura, H. J., eds.). New York: Elsevier, North-Holland Press. In press.
Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons. Evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol.25, 409–412 (1973).
Cotzias, G. C., van Waest, M. H., Schiffer, L. M.: Aromatic amino acids and modification of parkinsonism. New Engl. J. Med.276, 374–379 (1967).
Dougan, D., Wade, D., Mearrick, P.: Effects of L-DOPA metabolites at a dopamine receptor suggest a basis for “on-off” effects in Parkinson's disease. Nature254, 70–71 (1975).
Ehringer, H., Hornykiewicz, O.: Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankung des extrapyramidalen Systems. Klin. Wschr.38, 1236–1239 (1960).
Euvrad, C., Premont, J., Oberlander, C., Boissier, J. R., Bockaert, J.: Is dopamine-sensitive adenylate cyclase involved in regulating the activity of striatal cholinergic neurons? Naunyn-Schmiedeberg's Arch. Pharmacol.309, 241–245 (1979).
Flückiger, E., del Pozo, E.: Influence on the endocrine system. In: Handbook of Experimental Pharmacology, Vol. 49 (Berde, B., Schild, H. O., eds.), Ch. IX, pp. 615–690. Berlin-Heidelberg-New York: Springer. 1978.
Granerus, A. K., Carlsson, A., Svanborg, A.: The aging neuron. Influence on symptomatology and therapeutic response in Parkinson's symptoms. In: Advances in Neurobiology, Vol. 24 (Parrier, L. J., Sourkes, T. L., Bédard, P. J., eds.), pp. 327–334. New York: Raven Press. 1979.
Herrling, P., Hull, C. D.: Iontophoretically applied dopamine depolarizes and hyperpolarizes the membrane of cat caudate neurons. Brain Res.192, 441–462 (1980).
Hauser, D., Frick, W., Sauter, A. (Sandoz Ltd., Preclinical Research, Basle): Personal communication.
Kebabian, J. W., Calne, D. B.: Multiple receptors for dopamine. Nature277, 93–96 (1979).
Kebabian, J. W., Petzold, G. L., Greengard, P.: Dopamine sensitive adenylate cyclase in caudate nucleus of rat brain and its similarity to the dopamine receptors. Proc. Nat. Acad. Sci. U.S.A.69, 2145–2149 (1972).
König, J. F. R., Klippel, R. A.: The Rat Brain: A Stereotaxic Atlas. New York: Krieger. 1970.
Krüger, B. K., Forn, J., Walters, J. R., Roth, R. H.: Stimulation by dopamine of adenosine cyclic 3′, 5′-monophosphate formation in rat caudate nucleus: Effect of lesions of the nigro-neostriatal pathway. Mol. Pharmacol.12, 639–648 (1976).
Leysen, J. E., Niemegeers, C. J. E., Tollenaere, J. P., Laduron, P.: Serotoninergic component of neuroleptic receptors. Nature272, 168–171 (1978).
Markstein, R., Wagner, H.: Effect of dihydroergotoxine on cyclic AMP-generating systems in rat cerebral cortex slices. Gerontology24, Suppl. 1, 94–105 (1978).
Mitchell, P. R., Doggett, N. S.: Modulation of striatal3H-glutamic acid release by dopaminergic drugs. Life Sciences26, 2073–2081 (1980).
Nagy, I. I., Lee, T., Seeman, P., Fibiger, H. C.: Direct evidence for presynaptic and postsynaptic dopamine receptors in the brain. Nature274, 278–281 (1978).
Northup, J. K., Mansour, T. E.: Adenylate cyclase from Fasciola hepatica. 1. Ligand specificity of adenylate cyclase coupled serotonin receptors. Mol. Pharmacol.14, 804–819 (1978).
Schild, H. O.: pAX and competitive drug antagonism. Br. J. Pharmacol.4, 277–280 (1949).
Schwarcz, R., Creese, J., Coyle, J. T., Snyder, S.: Dopamine receptors localized on cerebral cortical afferents to rat corpus striatum. Nature271, 766–768 (1978).
Shoulson, J., Chase, T. N.: Clonidine and the antiparkinsonian response to L-DOPA or piribedil. Neuropharmacol.15, 25–27 (1976).
Starke, K.: Regulation of noradrenaline release by presynaptic receptor systems. Rev. Physiol. Biochem. Pharmac.77, 1–124 (1977).
Starke, K., Reimann, W., Zumstein, A., Hertting, G.: Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol.305, 27–36 (1978).
Stoof, J. C., Thieme, R. E., Vrijmoed de Vries, M. C., Mulder, A. H.: In vitro acetylcholine release from rat caudate nucleus as a new model for testing drugs with dopamine receptor activity. Naunyn-Schmiedeberg's Arch. Pharmacol.309, 119–124 (1979).
Tennysan, V. M., Heikkila, R., Mytilineou, C., Cote, L., Cohen, G.: 5-Hydroxydopamine “tagged” neuronal boutons in rabbit neostriatum: Interrelationship between vesicles and axonal membrane. Brain Res.82, 431–438 (1974).
Thal, L. J., Makman, M. H., Ahn, H. S., Mishra, R. K., Horowitz, S. G., Dvorkin, B., Katzman, R.:3H-spiroperidol binding and dopamine stimulated adenylate cyclase: Evidence for multiple classes of receptors in primate brain regions. Life Sciences23, 629–634 (1978).
Vigouret, J. M., Bürki, H. R., Jaton, A.-L., Züger, P. E., Loew, D.: Neurochemical and neuropharmacological investigations of four ergot derivatives: Bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712. Pharmacol.16, Suppl. 1, 156–173 (1978 a).
Vigouret, J. M., Jaton, A. L., Wagner, H. R., Loew, D.: Attempt to correlate effects of ergot derivatives with central dopaminergic stimulant properties in functional tests. Experientia34, 931B (1980 b).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Markstein, R. Neurochemical effects of some ergot derivatives: A basis for their antiparkinson actions. J. Neural Transmission 51, 39–59 (1981). https://doi.org/10.1007/BF01664004
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01664004